Ind-Swift Laboratories Ltd.
NSE: INDSWFTLAB | BSE: 532305
₹133.89
₹-0.72
(-0.53%)
As on 15-May-2026IST
Market cap
₹1,163 Cr
Revenue (TTM)
₹594 Cr
P/E Ratio
4.7
P/B Ratio
0.8
Div. Yield
0 %
Quality Score
4/10
Growth Score
6/10
Valuation Score
4/10
Momentum Score
10/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹249 Cr
-
ROE
24.7 %
-
ROCE
24.2 %
-
Industry P/E
37.98
-
EV/EBITDA
12.2
-
Debt to Equity
0
-
Book Value
₹158.8
-
EPS
₹6.3
-
Face value
10
-
Shares outstanding
86,836,558
10 Years Aggregate
CFO
₹600.18 Cr
EBITDA
₹1,459.36 Cr
Net Profit
₹646.43 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ind-Swift Lab
| 51.9 | -3.8 | -1.6 | 71.9 | 26.8 | 11.2 | 12.9 |
|
BSE Healthcare
| 8.7 | 11.0 | 10.7 | 11.7 | 26.8 | 14.4 | 11.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ind-Swift Lab
| -19.9 | 1.7 | 49.1 | 2.2 | 4.0 | 160.5 | -51.9 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ind-Swift Lab
|
133.9 | 1,163.2 | 594.5 | 248.5 | -5.0 | 3.5 | 4.7 | 0.8 |
| 1,044.6 | 12,824.4 | 2,551.8 | 564.5 | 28.3 | 18.4 | 22.7 | 3.8 | |
| 430.4 | 7,458.2 | 1,053.1 | 293.6 | 32.3 | 24.6 | 25.4 | 5.8 | |
| 1,135.3 | 11,870.3 | 1,158.7 | 309.6 | 31.9 | 17.3 | 38 | 6.3 | |
| 1,704.9 | 32,324.1 | 9,203.5 | 941.3 | 15.4 | 19.6 | 35 | 6.5 | |
| 370.3 | 4,048.6 | 159.3 | 47.8 | 39.0 | 18.6 | 84.7 | 14.6 | |
| 16,590.0 | 21,260.0 | 2,023.0 | 364.0 | 23.9 | 20.8 | 58.4 | 11.3 | |
| 2,292.5 | 3,796.8 | 707.5 | 115.2 | 17.8 | 19.4 | 33 | -- | |
| 1,050.4 | 4,846.5 | 649.5 | 121.6 | 23.7 | 13.2 | 42 | 5.2 | |
| 211.2 | 5,571.1 | 7.1 | -276.3 | -4,077.5 | -63.3 | -- | 9.4 |
Shareholding Pattern
View DetailsNews & Analysis
All News
Pledging Gamble Sours for these Companies
2 min read•By Vikas Vardhan
About Ind-Swift Lab
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic... areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is based in Manimajra, India. Read more
-
Incorporated
1995
-
Chairman
Navrattan Munjal
-
Managing Director
Navrattan Munjal
-
Headquarters
Chandigarh, Union Territory
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
Announcements
View AnnouncementsClarification On Spurt In Volume
09-Apr-2026No News & Announcements are available.
FAQs for Ind-Swift Lab
What is the current share price of Ind-Swift Laboratories Ltd Today?
The share price of Ind-Swift Laboratories Ltd is ₹133.89 (NSE) and ₹133.95 (BSE) as of 15-May-2026 IST. Ind-Swift Laboratories Ltd has given a return of 26.75% in the last 3 years.
What is the current PB & PE ratio of Ind-Swift Laboratories Ltd?
The P/E ratio of Ind-Swift Laboratories Ltd is 4.68 times as on 15-May-2026, a 88 discount to its peers’ median range of 37.98 times.
The P/B ratio of Ind-Swift Laboratories Ltd is 0.84 times as on 15-May-2026, a 64 discount to its peers’ median range of 2.32 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
2.30
|
0.53
|
|
2024
|
1.38
|
0.62
|
|
2023
|
6.86
|
0.66
|
|
2022
|
0.00
|
0.97
|
|
2021
|
0.00
|
1.09
|
What is the 52 Week High and Low of Ind-Swift Laboratories Ltd?
The 52-week high and low of Ind-Swift Laboratories Ltd are Rs 156.80 and Rs 70.71 as of 17-May-2026.
What is the market cap of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd has a market capitalisation of ₹ 1,163 Cr as on 15-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Ind-Swift Laboratories Ltd?
Before investing in Ind-Swift Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.